Skip to navigation bar Skip to breadcrumbs Skip to page content
clear place holder
Envelope icon E-mail Updates Teal square Text size:  a A A

Clinical Summary

Chlamydia and Gonorrhea: Screening

Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Screening for Chlamydia and Gonorrhea: Clinical Summary of USPSTF Recommendation

Population Sexually active females aged ≤24 y and older women at increased risk for infection Sexually active females aged ≤24 y and older women at increased risk for infection Men
Recommendation Screen for chlamydia.
Grade: B
Screen for gonorrhea.
Grade: B
No recommendation.
Grade: I statement
Risk Assessment Age is a risk factor for chlamydial and gonococcal infections, with the highest infection rates occurring in women aged 20 to 24 y. Other risk factors include new or multiple sex partners, a sex partner with concurrent partners, or a sex partner with a sexually transmitted infection (STI); inconsistent condom use among persons who are not in mutually monogamous relationships; previous or concurrent STI; and exchanging sex for money or drugs.
Screening Tests Chlamydial and gonococcal infections are diagnosed by using nucleic acid amplification tests, which are approved by the U.S. Food and Drug Administration for use on urogenital sites, including male and female urine; clinician-collected endocervical, vaginal, and male urethral specimens; and self-collected vaginal specimens in clinical settings.
Treatment and Interventions Chlamydial and gonococcal infections respond to treatment with antibiotics. Posttest counseling is also an integral part of management of patients with a newly diagnosed STI. Counseling should address safe sex practices that can reduce disease transmission or reinfection.
Balance of Benefits and Harms Screening for chlamydia has a moderate net benefit in females aged ≤24 y and older women at increased risk for infection Screening for gonorrhea has a moderate net benefit in females aged ≤24 y and older women at increased risk for infection. The current evidence is insufficient to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men.
Other Relevant USPSTF Recommendations The USPSTF has recommendations on screening for other STIs, including hepatitis B, genital herpes, HIV, and syphilis, and behavioral counseling for all sexually active adolescents and for adults who are at increased risk for STIs. These recommendations are available at http://www.uspreventiveservicestaskforce.org.

For a summary of the evidence systematically reviewed in making these recommendations, the full recommendation statement, and supporting documents, please go to http://www.uspreventiveservicestaskforce.org.

Disclaimer: Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.


Current as of September 2014

Current as of: September 2014

Internet Citation: Clinical Summary: Chlamydia and Gonorrhea: Screening. U.S. Preventive Services Task Force. October 2014.
https://www.uspreventiveservicestaskforce.org/Page/Document/ClinicalSummaryFinal/chlamydia-and-gonorrhea-screening

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857